Washington Technology Center - EKOS Corporation

CLIENTS & PARTNERS

Our Clients

>	Alphabetical Client List

EKOS Corporation

>	Clients by Legislative District

>	Olympic Peninsula Clients

>	King County Clients

>	Northwest Washington Clients

>	South Puget Sound Clients

>	Southwest Washington Clients

>	Central Washington Clients

>	Northeast Washington Clients

>	Southeast Washington Clients

Our Partners

EKOS Corporation

Bothell

http://www.ekoscorp.com About EKOS Corporation EKOS^® Corporation pioneered the development and clinical application of microsonic technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists and vascular surgeons at leading institutions across the nation use EKOS MicroSonic™ Accelerated Thrombolysis to provide faster, safer and more complete dissolution of thrombus. In 2008, the company introduced its next generation EkoSonic™ Endovascular System with Rapid Pulse Modulation. The EkoSonic system is FDA cleared for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. It is currently used to treat patients with peripheral arterial occlusions (PAO) and deep vein thrombosis (DVT) and additional applications are being investigated. For more information visit www.EKOScorp.com.

Research & Technology Development (RTD) Award: Phase I Project Title: “Development of an algorithm to accurately predict ‘end of therapy’ in ultrasound-facilitated Thrombolysis” Research Partner: Hong Shen, Ph.D., Assistant Professor, Chemical Engineering, University of Washington Project Began: 2008 EKOS Corporation, a Bothell-based medical device company, is teamed with the University of Washington Department of Chemical Engineering to improve the company’s proprietary catheter-based drug-delivery system. UW will receive $30,000 in Phase I Research and Technology Development funding from Washington Technology Center and $6,000 from EKOS for the project titled “Development of an algorithm to accurately predict ‘end of therapy’ in ultrasound-facilitated Thrombolysis.” Catheter-directed thrombolysis (CDT) is a therapy for patients with vascular diseases such as deep vein thrombosis. However, current use of CDT is associated with high costs. These costs are due to technology limitations that result in doctors prescribing larger than necessary drug dosages and longer durations of therapy. In this Phase I project, the collaborative team of EKOS and UW Assistant Professor Hong Shen plan to analyze patient data to develop an algorithm that will better predict the end of CDT therapy. Follow-on projects will involve the development and launch of the resulting software upgrade. EKOS plans to add this new technology to its current product line, potentially making CDT a more attractive and economical treatment option for doctors and patients.				"Investing in our communities and businesses through economic development really does enhance people's lives and our business climate. This research and development funding to EKOS is geared to develop ways to lower costs of essential medical treatment for those with vascular problems. To these people and their families, this work quite possibly can make a world of difference. These continued funding grants are targeted investments that help a lot of people." State Sen. Rosemary McAuliffe (D-Bothell). “This is great news for the research industry in the Bothell area. I’m very happy to hear about the partnership, and I hope that there are many more like it.” State Rep. Al O’Brien (D-Mountlake Terrace)

Focused Technology Initiative (FTI) Award

Research Partner: Fatih Dogan, UW Dept. of Materials Science & Engineering

Project began: 2001

Founded in 1995, EKOS is focused on developing proprietary ultrasound-based systems and devices for local drug delivery. Highly reliable piezoelectric ceramic transducers are crucial to the success of the devices developed by EKOS. This project works towards the development of such transducers by identifying the failure mechanisms of the ceramic material and developing improved material strength.